Bioextrax (BIOEX) Q1 2026 earnings summary

Executive summary

• Focus on licensing bioplastic (PHA), protein, and microfiber technologies from renewable sources, with several ongoing customer projects and new commercial agreements.

• Significant progress in industrial-scale implementation, including a major licensing deal in Western Asia and continued collaboration with leading industry partners.

Financial highlights

• Net sales for Q1 2026 were SEK 185k, up from SEK 79k year-over-year.

• Operating loss was SEK -4,329k, compared to SEK -3,989k in Q1 2025.

• Net result per share was SEK -0.09, an improvement from SEK -0.10 year-over-year.

• Cash flow for the period was SEK 7,630k, compared to SEK -5,132k in Q1 2025, mainly due to a rights issue.

• Cash and cash equivalents at March 31, 2026, were SEK 11,561k.

Outlook and guidance

• Ongoing commercialization efforts with multiple potential customers and partners, aiming for additional commercial license agreements.

• Positive cash flow possible if one or more commercial agreements are signed; further financing may be needed depending on timing and expansion plans.